{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:51:12Z","timestamp":1789872672679,"version":"4.0.1"},"reference-count":29,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2012,3,14]],"date-time":"2012-03-14T00:00:00Z","timestamp":1331683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>A week 48 efficacy and safety analysis with respect to gender and race was conducted using pooled data from the phase <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content>, double\u2010blind, double\u2010dummy efficacy comparison in treatment\u2010na\u00efve, HIV\u2010infected subjects of TMC278 and efavirenz (<jats:styled-content style=\"fixed-case\">ECHO<\/jats:styled-content>) and TMC278 against HIV, in a once\u2010daily regimen versus efavirenz (<jats:styled-content style=\"fixed-case\">THRIVE<\/jats:styled-content>) trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Treatment\u2010na\u00efve, <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u20101\u2010infected adults were randomized to receive rilpivirine (<jats:styled-content style=\"fixed-case\">RPV<\/jats:styled-content>; <jats:styled-content style=\"fixed-case\">TMC<\/jats:styled-content>278) 25\u2009mg once a day (qd), or efavirenz (<jats:styled-content style=\"fixed-case\">EFV<\/jats:styled-content>) 600\u2009mg qd, plus tenofovir\/emtricitabine (<jats:styled-content style=\"fixed-case\">ECHO<\/jats:styled-content>) or tenofovir\/emtricitabine, zidovudine\/lamivudine or abacavir\/lamivudine (<jats:styled-content style=\"fixed-case\">THRIVE<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1368 participants (76% male and 61% White, of those with available race data) were randomized and treated. No gender\u2010related differences in response rate (percentage of patients with <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u20101 viral load &lt;\u200950 <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u20101 <jats:styled-content style=\"fixed-case\">RNA<\/jats:styled-content> copies\/<jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content>, using an intent\u2010to\u2010treat, time\u2010to\u2010loss\u2010of\u2010virological\u2010response algorithm) were observed (<jats:styled-content style=\"fixed-case\">RPV<\/jats:styled-content>: men, 85%; women, 83%; <jats:styled-content style=\"fixed-case\">EFV<\/jats:styled-content>: men, 82%; women, 83%). Response rates were lower in Black compared with <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>sian and White participants (<jats:styled-content style=\"fixed-case\">RPV<\/jats:styled-content>: 75% <jats:italic>vs.<\/jats:italic> 95% and 85%, respectively; <jats:styled-content style=\"fixed-case\">EFV<\/jats:styled-content>: 74% <jats:italic>vs.<\/jats:italic> 93% and 83%, respectively); this finding was mostly a result of higher discontinuation and virological failure rates in Black patients. Safety findings were generally similar across race and gender subgroups. However, nausea occurred more commonly in women than in men in both treatment groups. In men, diarrhoea was more frequent in the <jats:styled-content style=\"fixed-case\">EFV<\/jats:styled-content> group, and abnormal dreams\/nightmares were more frequent in men in both the <jats:styled-content style=\"fixed-case\">EFV<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">RPV<\/jats:styled-content> groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Overall response rates were high for both <jats:styled-content style=\"fixed-case\">RPV<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">EFV<\/jats:styled-content>. No gender differences were observed. However, response rates were lower among Black patients, regardless of treatment group. Gender appeared to influence the incidence of gastrointestinal adverse events and abnormal dreams\/nightmares for both treatments.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2012.00991.x","type":"journal-article","created":{"date-parts":[[2012,3,15]],"date-time":"2012-03-15T03:18:29Z","timestamp":1331781509000},"page":"406-415","source":"Crossref","is-referenced-by-count":38,"title":["Effect of gender and race on the week 48 findings in treatment\u2010na\u00efve, <scp>HIV<\/scp>\u20101\u2010infected patients enrolled in the randomized, phase <scp>III<\/scp> trials <scp>ECHO<\/scp> and <scp>THRIVE<\/scp>"],"prefix":"10.1111","volume":"13","author":[{"given":"S","family":"Hodder","sequence":"first","affiliation":[{"name":"UMDNJ\u2010New Jersey Medical School  Newark NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Arasteh","sequence":"additional","affiliation":[{"name":"EPIMED c\/o Auguste\u2010Viktoria\u2010Clinic  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"De Wet","sequence":"additional","affiliation":[{"name":"Spectrum Health  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Gathe","sequence":"additional","affiliation":[{"name":"Therapeutic Concepts \u2013 Donald R. Watkins Foundation  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Gold","sequence":"additional","affiliation":[{"name":"Albion Street Centre  Surry Hills NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Kumar","sequence":"additional","affiliation":[{"name":"Infectious Diseases Georgetown University Hospital  Washington, DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Mohapi","sequence":"additional","affiliation":[{"name":"Perinatal HIV Research Unit University of the Witwatersrand  Johannesburg South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Short","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Jefferson Medical College of Thomas Jefferson University  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Crauwels","sequence":"additional","affiliation":[{"name":"Tibotec BVBA  Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Vanveggel","sequence":"additional","affiliation":[{"name":"Tibotec BVBA  Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Boven","sequence":"additional","affiliation":[{"name":"Tibotec Inc.  Titusville NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,3,14]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq457"},{"key":"e_1_2_6_3_1","unstructured":"da SilvaA CohenD GibbsSet\u2009al.Impact of gender on response to lopinavir\/ritonavir (LPV\/r) tablets dosed QD or BID administered with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) in antiretroviral\u2010na\u00efve (ARV) subjects: results from Study M05\u2010730.17th International AIDS Conference. Mexico City Mexico August2008[Abstract TUPE0069]."},{"key":"e_1_2_6_4_1","unstructured":"FourieJ FlammJ Rodriguez\u2010FrenchAet\u2009al.ARTEMIS: week 96 safety and efficacy of darunavir\/r by gender age and race.5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Cape Town South Africa July2009[Abstract CDB072]."},{"key":"e_1_2_6_5_1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/QAI.0b013e31813e5e20","article-title":"Response to efavirenz\u2010containing regimens in previously antiretroviral\u2010naive HIV\u2010positive patients: the role of gender","volume":"46","author":"Smith CJ","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_6_6_1","unstructured":"SmithK TierneyC DaarEet\u2009al.Association of race\/ethnicity and sex on outcomes in ACTG Study A5202.18th Conference on Retroviruses and Opportunistic Infections. Boston MA February2011[Abstract 536]."},{"key":"e_1_2_6_7_1","unstructured":"CampbellT SmeatonL KumarasamyNet\u2009al.Efficacy and safety of EFV with either co\u2010formulated 3TC\/ZDV or FTC\/TDF for initial treatment of HIV\u20101\u2010infected men and women in diverse multinational settings: ACTG PEARLS Study.18th Conference on Retroviruses and Opportunistic Infections. Boston MA February2011[Abstract 149LB]."},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1310\/M47B-R51C-X0MC-K3GW"},{"key":"e_1_2_6_9_1","unstructured":"HodderS JayaweeraD MrusJ RyanR WitekJ on behalf of the GRACE Study Group.GRACE (Gender Race And Clinical Experience): Etravirine (ETR) subgroup analysis at week 48.49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco CA September2009[Abstract H\u2010919]."},{"key":"e_1_2_6_10_1","unstructured":"KumarP CurrierJ SquiresKet\u2009al.Predictors of response in GRACE (Gender Race And Clinical Experience).47th Annual Meeting of the Infectious Diseases Society of America. Philadelphia PA 2009[Abstract 335]."},{"key":"e_1_2_6_11_1","unstructured":"SmithK GarciaF RyanR FalconR TennenbergA MrusJ.GRACE (Gender Race And Clinical Experience): outcomes by race at week 48.49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco CA September2009[Abstract H\u2010918]."},{"key":"e_1_2_6_12_1","unstructured":"SmithK KumarP PatelPet\u2009al.Differences in virologic response among African\u2010Americans and females regardless of therapy in the HEAT study.5th Conference on HIV Pathogenesis Treatment and Prevention. Cape Town South Africa July2009[Abstract MOPEB033]."},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31815ac499"},{"key":"e_1_2_6_14_1","unstructured":"RibaudoH SmithK RobbinsGet\u2009al.Race differences in the efficacy of initial ART on HIV infection in randomized trials undertaken by ACTG.18th Conference on Retroviruses and Opportunistic Infections. Boston MA February2011[Abstract 50]."},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200404150-00014"},{"key":"e_1_2_6_16_1","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc.Viramune\u00ae (nevirapine) prescribing information February 2011.2011. Available athttp:\/\/bidocs.boehringer\u2010ingelheim.com\/BIWebAccess\/ViewServlet.ser?docBase=renetnt&folderPath=\/Prescribing+Information\/PIs\/Viramune\/Viramune.pdf(accessed 16 February 2011)."},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1086\/431606"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-153-6-201009210-00002"},{"key":"e_1_2_6_19_1","unstructured":"Janssen Therapeutics.EDURANT\u2122 (rilpivirine) tablets prescribing information. May2011. Available atwww.edurant\u2010info.com\/patients\/full\u2010product\u2010information(accessed 17 August 2011)."},{"key":"e_1_2_6_20_1","unstructured":"Gilead Sciences.COMPLERA\u2122 (emtricitabine\/rilpivirine\/tenofovir disoproxil fumarate) tablets prescribing information. August.2011. Available atwww.gilead.com\/pdf\/complera_pi.pdf(accessed 17 August 2011)."},{"key":"e_1_2_6_21_1","unstructured":"CohenC MolinaJ\u2010M CahnP ClotetBet\u2009al.Pooled week 48 efficacy and safety results from ECHO and THRIVE two double\u2010blind randomised phase III trials comparing TMC278 versus efavirenz in treatment\u2010na\u00efve HIV\u20101\u2010infected patients.18th International AIDS Conference. Vienna Austria July2010[Abstract THLBB206]."},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833032ed"},{"key":"e_1_2_6_23_1","unstructured":"WilkinA PozniakAL Morales\u2010RamirezJet\u2009al.TMC278 shows favorable tolerability and non\u2010inferior efficacy compared to efavirenz over 192 weeks in HIV\u20101\u2010infected treatment\u2010na\u00efve patients.19th Annual Canadian Conference on HIV\/AIDS Research. Saskatoon Canada May2010[Abstract 7214]."},{"key":"e_1_2_6_24_1","unstructured":"DesmidtM WillemsB DomPet\u2009al.Absence of a teratogenic potential from a novel next\u2010generation NNRTI TMC278.12th European AIDS Conference. Cologne Germany November2009[Abstract PE7.1\/4]."},{"key":"e_1_2_6_25_1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/135965350901400114","article-title":"Compilation and prevalence of mutations associated with resistance to non\u2010nucleoside reverse transcriptase inhibitors","volume":"14","author":"Tambuyzer L","year":"2009","journal-title":"Antivir Ther"},{"key":"e_1_2_6_26_1","unstructured":"AIDS Clinical Trials Group 2004 (clarification 2009).Division of AIDS table for grading the severity of adult and pediatric adverse events version 1.0. December2004. Clarification August 2009. Available athttp:\/\/rsc.tech\u2010res.com\/safetyandpharmacovigilance(accessed 9 February 2011)."},{"key":"e_1_2_6_27_1","unstructured":"Medical Dictionary for Regulatory Activities Terminology (MedDRA) version 11.0.International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).2008. Available athttp:\/\/meddramsso.com(accessed 9 February 2011)."},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528120-00003"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283390db3"},{"key":"e_1_2_6_30_1","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS).Global report: UNAIDS report on the global AIDS epidemic.2010. Available atwww.unaids.org\/documents\/20101123_GlobalReport_Chap2_em.pdf(accessed 16 January 2011)."}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2012.00991.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2012.00991.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T16:50:09Z","timestamp":1697388609000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2012.00991.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,14]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1111\/j.1468-1293.2012.00991.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2012.00991.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,14]]}}}